Question-and-Answer Session
Operator
(Operator Instructions). Your first question comes from Ian Sanderson of Cowen and Company. Please go ahead, sir.
Ian Sanderson
Good morning, and thank for taking the question. And forgive me if this is delineated in the Form 10. But on the improved formulation of Oncaspar, will the development responsibility for that rest with Enzon or with Evivrus? And the second question is on Oncaspar performance for the quarter, you mentioned that prescription -- or the volume was up I believe it was –
Jeff Buchalter
13%
Ian Sanderson
13% and so presumably price accounts for the rest. But can you talk a little bit about what we should expect for pricing going forward?
Jeff Buchalter
Let me say first of all, yes, the residual R&D for Oncaspar and Andagen will stay with the remaining company of Enzon, the responsibility obviously to support the currently marketed brands. And you're correct in that. And second of all in terms of the price increase, we've had pretty good price increases in the last year on both Oncaspar Andagen. That really is to put money back into the required R&D funding. So again, you're right that we've taken those price increases two years in a row at over 20%.
Ian Sanderson
And have you done similar price increases for Abalcet or is the market too competitive?
Jeff Buchalter
It's too competitive for any pricing.0:18
Ian Sanderson
Thank you.
Operator
Thank you (Operator Instructions). Next question is from Matt Renna of Soleil-Neponset. Please go ahead.
Matt Renna
Good morning guys congrats on very nice quarter. Thank for taking the questions.
Craig Tooman
Thank you.
Matt Renna
I just want to elaborate on the last question with regards to pricing on Oncaspar. Obviously you guys have done a nice job of growing volumes in the face of pretty healthy price increases. Going forward do you see really any more significant pricing flexibility on that asset?
Jeff Buchalter
Let me handle that, Matt. As I've always indicated, there was some elasticity in the product, and I think the rationale for the price is because of the increase cost of developing the subsequent product. This is on the strategy that we are using as a primary strategy with other recognizing the increased costs associated with developing now a new recombinant form.
Matt Renna
Great. And then Craig, after capitalizing the new company, your cash balance will be relatively low, and this obviously implies that you're pretty comfortable with the initial cash flow of the underlying business. Can you maybe provide some color on that dynamic?
- To read the full transcript on Seeking Alpha, click here »
